|
rs13181
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Our meta-analysis included eleven studies in which four SNPs (ERCC1 rs11615 and rs3212986, ERCC2 rs13181 and rs1799793) reportedly associated with osteosarcoma prognosis were investigated.
|
28977987 |
2017 |
|
rs13181
|
|
|
0.080 |
GeneticVariation |
BEFREE |
This study did not support rs11615, rs13181 or rs1799793 to be used as surrogate markers for clinical outcome of osteosarcoma with chemotherapy.
|
30544402 |
2018 |
|
rs13181
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Multivariate logistic regression analysis did not reveal significant associations between ERCC2 rs13181/rs1799793 or ERCC3 rs4150441/ rs4150506 gene polymorphisms and the development of osteosarcoma in codominant, dominant, and recessive models.
|
27051024 |
2016 |
|
rs13181
|
|
|
0.080 |
GeneticVariation |
BEFREE |
We first report associations of four SNPs, ERCC1 Asn118Asn, ERCC1 Gln504Lys, ERCC2 Asp312Asn and ERCC2 Lys751Gln, with risk of death from osteosarcoma in a Chinese population, indicating ERCC1 118T/T and ERCC2 A/A may be used as surrogate markers for clinical outcome of osteosarcoma treatment with cisplatin.
|
23098477 |
2012 |
|
rs13181
|
|
|
0.080 |
GeneticVariation |
BEFREE |
In summary, the ERCC2 Lys751Gln and ERCC5 His46His polymorphisms might influence osteosarcoma prognosis.
|
25023406 |
2014 |
|
rs13181
|
|
|
0.080 |
GeneticVariation |
BEFREE |
Our study indicated that GSTP1 and ERCC2 Lys751Gln polymorphisms might be candidate pharmacogenomic factors to be explored in the future to identify osteosarcoma patients who might benefit from chemotherapy.
|
23317281 |
2012 |
|
rs1042522
|
|
|
0.040 |
GeneticVariation |
BEFREE |
In the present meta-analysis, we aimed to elucidate the associations of TP53 rs1042522 genetic polymorphism with the risk of osteosarcoma or Ewing sarcoma.
|
30833364 |
2019 |
|
rs1042522
|
|
|
0.040 |
GeneticVariation |
BEFREE |
These data do not indicate a strong link between variation in TP53 and OS risk, although they provide preliminary evidence of an increased risk of OS associated with variants at IVS2+38 and Pro72Arg.
|
17096406 |
2007 |
|
rs1042522
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The study provides evidence supporting the association of MDM2 SNP309 with high-grade osteosarcoma risk in females and shows that TP53 Arg72Pro has a prognostic value for overall survival and EFS in osteosarcoma patients.
|
19451596 |
2009 |
|
rs1042522
|
|
|
0.040 |
GeneticVariation |
BEFREE |
We found that subjects carrying rs12951053 CC genotype and rs1042522</span> GG genotype were significantly associated with risk of OS [odds ratio (OR)=1.68, 95% confidence intervals (CI): 1.05-2.68; OR=1.89, 95% CI: 1.16-3.07] compared with subjects carrying the common genotypes.
|
26045840 |
2015 |
|
rs861539
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Moreover, XRCC3 Thr241Met gene polymorphism was correlated with an elevated increased risk of osteosarcoma</span> in dominant (OR = 1.55, 95% CI = 1.03-2.34) and recessive models (OR = 2.30, 95% CI = 1.16-4.56).
|
26617908 |
2015 |
|
rs861539
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Association between the DNA Repair Gene XRCC3 rs861539 Polymorphism and Risk of Osteosarcoma: a Systematic Review and Meta-Analysis
|
28345844 |
2017 |
|
rs861539
|
|
|
0.040 |
GeneticVariation |
BEFREE |
XRCC3 Thr241Met gene polymorphism was associated with osteosarcoma risk, but XRCC3 Thr241Met CC genotype was not associated with Enneking stage, tumor location, and tumor metastasis.
|
30539867 |
2018 |
|
rs861539
|
|
|
0.040 |
GeneticVariation |
BEFREE |
In conclusion, our study firstly reports that XRCC3 Thr241Met gene polymorphism is associated with an elavated risk of osteosarcoma.
|
26662447 |
2015 |
|
rs3212986
|
|
|
0.030 |
GeneticVariation |
BEFREE |
ERCC1 (C118T (rs11615) and C8092A (rs3212986)) and ERCC2 (A751C (rs171140) and G312A (rs1799793)) polymorphisms were analysed in 44 patients with osteosarcoma, who were treated with cisplatin based neoadjuvant chemotherapy.
|
29980176 |
2018 |
|
rs3212986
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Our meta-analysis included eleven studies in which four SNPs (ERCC1 rs11615 and rs3212986, ERCC2 rs13181 and rs1799793) reportedly associated with osteosarcoma prognosis were investigated.
|
28977987 |
2017 |
|
rs3212986
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The ERCC2-rs1799793 AA+AC > CC (OR=1.3428, 95% CI=1.0201; 1.7674) had an effect on the risk of osteosarcoma development, whereas, there were no significant associations among the other ERCC SNPs (ERCC1 rs3212986, ERCC1 rs11615, and ERCC2 rs13181) and osteosarcoma.
|
30402838 |
2018 |
|
rs1047768
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Here, we performed a meta-analysis to determine the strength of the association between eight polymorphisms in the <i>ERCC</i> genes (rs11615, rs3212986, rs2298881, rs13181, rs1799793, rs1800067, rs2296147, and rs1047768) and prognosis of osteosarcoma patients treated with chemotherapy.
|
29950854 |
2018 |
|
rs1047768
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our findings showed polymorphisms in ERCC5 rs1047768 and MMS19L rs29001322 to be associated with clinical outcome of osteosarcoma patients undergoing chemotherapy.
|
23679317 |
2013 |
|
rs1128503
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We conclude that ABCC3 rs4148416 polymorphism was significantly associated with poor osteosarcoma response and ABCB1 rs1128503 polymorphism was significantly associated with good osteosarcoma response in Caucasian population rather than Asian population.
|
26107220 |
2015 |
|
rs1128503
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The <i>ABCB1</i> (C1236T) polymorphism affects P-gp-mediated transport of osteosarcoma drugs in a drug-specific way.
|
30977678 |
2019 |
|
rs1131691014
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The study provides evidence supporting the association of MDM2 SNP309 with high-grade osteosarcoma risk in females and shows that TP53 Arg72Pro has a prognostic value for overall survival and EFS in osteosarcoma patients.
|
19451596 |
2009 |
|
rs1131691014
|
|
|
0.020 |
GeneticVariation |
BEFREE |
These data do not indicate a strong link between variation in TP53 and OS risk, although they provide preliminary evidence of an increased risk of OS associated with variants at IVS2+38 and Pro72Arg.
|
17096406 |
2007 |
|
rs1690916
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In conclusion, the present meta-analysis indicates that MDM2 rs1690916 and rs2279744 cannot be considered as genetic risk factors for OS susceptibility in the different populations.
|
27438225 |
2016 |
|
rs1690916
|
|
|
0.020 |
GeneticVariation |
BEFREE |
MDM2 rs1690916 polymorphism was also associated with a risk of osteosarcoma (OR = 0.60, 95 % CI 0.46-0.77, P < 0.001).
|
24122202 |
2014 |